Comparison of demographics and G-CSF dosing among patients who converted to MDS/AML and those who did not convert
| . | Nonconverters (n = 321) . | Converters (n = 31) . |
|---|---|---|
| Sex | ||
| Male, n (%) | 164 (51) | 18 (58) |
| Female, n (%) | 157 (49) | 13 (42) |
| Age | ||
| Mean (SD), y | 11.1 (9.4) | 13.6 (10.1) |
| Median (range), y | 9.7 (0.3-45.2) | 12.4 (2.3-49.3) |
| Dose of G-CSF | ||
| Mean (SD), μg/kg/day | 13.2 (23.7) | 14.4 (12.2) |
| Median (range), μg/kg/day | 6 (0.1-240) | 12 (1-58) |
| Duration of G-CSF | ||
| Mean (SD), y | 4.5 (3.1) | 4.9 (2.4) |
| Median (range), y | 3.9 (0.1-10.5) | 4.9 (0.1-9.1) |
| . | Nonconverters (n = 321) . | Converters (n = 31) . |
|---|---|---|
| Sex | ||
| Male, n (%) | 164 (51) | 18 (58) |
| Female, n (%) | 157 (49) | 13 (42) |
| Age | ||
| Mean (SD), y | 11.1 (9.4) | 13.6 (10.1) |
| Median (range), y | 9.7 (0.3-45.2) | 12.4 (2.3-49.3) |
| Dose of G-CSF | ||
| Mean (SD), μg/kg/day | 13.2 (23.7) | 14.4 (12.2) |
| Median (range), μg/kg/day | 6 (0.1-240) | 12 (1-58) |
| Duration of G-CSF | ||
| Mean (SD), y | 4.5 (3.1) | 4.9 (2.4) |
| Median (range), y | 3.9 (0.1-10.5) | 4.9 (0.1-9.1) |